Stock listing
Cullinan Therapeutics, Inc.
Selected listing: CGEM · NASDAQ · USD · US
Cullinan Therapeutics, Inc. (NASDAQ:CGEM), Health Technology. Latest release Oct 1, 2026: New Drug Application Submission Initiated for Zipalertinib Plus…
- Ticker
- NASDAQ:CGEM
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM) is a public company based in the United States, focusing on innovative cancer therapies. The company is committed to addressing unmet medical needs in oncology through its research and development efforts.
Latest news from Cullinan Therapeutics, Inc.
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
October 1, 2026
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
September 24, 2026
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 21, 2026
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
September 14, 2026
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
September 13, 2026
Research Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. company profile
View the public company page for Cullinan Therapeutics, Inc. on 6ix.
Cullinan Therapeutics, Inc. news
Read company news and market updates connected to Cullinan Therapeutics, Inc..
Cullinan Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Cullinan Therapeutics, Inc..